Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Year-long trial finds NAD-boosting supplement fails to improve early Parkinson's symptoms (opens in a new tab)

news-medical.net · 2026-10-12

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 3 supported
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Three of five claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

  • 3 supported
  • 2 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredAmong secondary outcomes, only the Non-Motor Symptoms Scale differed significantly, with symptoms slightly worsening on nicotinamide riboside and improving on placebo.View evidenceHide evidence

As statedadjusted between-group difference of 4.22 points

Why this verdict

The abstract-level profile supports that, among five prespecified key secondary outcomes, four showed no significant difference and NMSS worsened more with nicotinamide riboside, with adjusted mean difference 4.22 points. However, the claim’s more specific statement that NMSS increased slightly with nicotinamide riboside and decreased with placebo is not available in the supplied abstract-depth profile, so that part is not verifiable at this depth.

1

Study evidence

Nonmotor symptom burden (NMSS) worsened more with nicotinamide riboside than with placebo over 52 weeks.Adjusted mean difference 4.22 points (95% CI, 1.07–7.37); P = .009

“The 5 key secondary outcomes were the individual parts I, II, and III of the MDS-UPDRS; dopamine transporter single-photon emission computed tomography brain imaging findings; and the Non-Motor Symptoms Scale score (NMSS).”
Claim 2 of 5Not coveredExploratory analyses showed marked increases in blood NAD levels with nicotinamide riboside, but no statistically significant difference in cerebral NAD-to-ATP ratio on brain spectroscopy.View evidenceHide evidence

As statedmean between-group blood NAD difference of 30 μM

Why this verdict

The supplied abstract-depth paper profile does not include exploratory blood NAD measurements or cerebral NAD-to-ATP ratio spectroscopy results. It reports clinical outcomes, DAT SPECT as a secondary endpoint, and safety, but not the biomarker/spectroscopy details needed to verify this claim.

Claim 3 of 5SupportedA recent randomized controlled trial published in JAMA found that oral nicotinamide riboside did not improve outcomes in people with early Parkinson's disease and was associated with modestly worse clinical scores than placebo.View evidenceHide evidence

As statedmodestly worse clinical scores

Why this verdict

The abstract-level profile supports that this was a randomized, double-blind, placebo-controlled phase 3 trial in early Parkinson disease and that nicotinamide riboside did not improve the primary clinical outcome versus placebo. It also reports a statistically worse MDS-UPDRS change with nicotinamide riboside, with an adjusted mean difference of 2.72 points favoring placebo. Calling this difference modest is consistent with the profile’s caveat that it was below clinically important worsening thresholds.

1

Study evidence

In the primary efficacy analysis, 52 weeks of nicotinamide riboside resulted in a statistically worse change in total MDS‑UPDRS compared with placebo.Adjusted mean difference 2.72 points (95% CI, 0.47–4.98) favoring placebo; P = .02

“Randomized, double-blind, placebo-controlled, phase 3 clinical trial conducted at 11 centers in Norway.”
Claim 4 of 5SupportedThe NOPARK trial enrolled 410 participants with early Parkinson's disease at 11 centers in Norway and randomized them to nicotinamide riboside 500 mg twice daily or placebo for 52 weeks.View evidenceHide evidence

As stated410 participants; 52 weeks

Why this verdict

The profile supports the design and setting details: 410 participants randomized at 11 centers in Norway, nicotinamide riboside 500 mg twice daily versus matching placebo, for 52 weeks, in early-stage Parkinson disease.

1

Study evidence

In the primary efficacy analysis, 52 weeks of nicotinamide riboside resulted in a statistically worse change in total MDS‑UPDRS compared with placebo.Adjusted mean difference 2.72 points (95% CI, 0.47–4.98) favoring placebo; P = .02

“Randomized, double-blind, placebo-controlled, phase 3 clinical trial conducted at 11 centers in Norway.”
Claim 5 of 5SupportedThe primary outcome was change in total MDS-UPDRS score, and at week 52 the nicotinamide riboside group had a higher mean score increase than placebo, with an adjusted difference of 2.72 points favoring placebo and reaching statistical significance.View evidenceHide evidence

As statedadjusted mean difference 2.72 points

Why this verdict

The profile directly supports the primary outcome and numerical result: change in total MDS-UPDRS parts I-III at week 52, nicotinamide riboside +2.45 versus placebo -0.27, adjusted mean difference 2.72 points favoring placebo, 95% CI 0.47 to 4.98, P=.02.

1

Study evidence

In the primary efficacy analysis, 52 weeks of nicotinamide riboside resulted in a statistically worse change in total MDS‑UPDRS compared with placebo.Adjusted mean difference 2.72 points (95% CI, 0.47–4.98) favoring placebo; P = .02

“Randomized, double-blind, placebo-controlled, phase 3 clinical trial conducted at 11 centers in Norway.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Safety/tolerability finding: serious adverse events occurred in 17/205 participants receiving nicotinamide riboside and 29/205 receiving placebo in the safety population.

    The story focuses on efficacy and biomarkers and does not report the abstract-level safety result. This omission matters because the trial’s harms profile is a prespecified secondary contribution and could temper interpretation of clinical worsening.

    From Randomized, double-blind, placebo-controlled phase 3 trial — safety population analysis

  • Population/generalizability limitation: participants were restricted to early-stage, DAT-confirmed Parkinson disease, diagnosed within 2 years, Hoehn & Yahr stage <3, with stable dopaminergic treatment before enrollment.

    The story says early Parkinson disease, but it does not reflect the DAT-confirmation, disease-stage, diagnosis-duration, and stable-treatment restrictions that limit generalization beyond this trial population.

    From Randomized, double-blind, placebo-controlled phase 3 trial; Randomized, double-blind, placebo-controlled phase 3 RCT; 52

4 things the story did carry across
  • NOPARK trial design and intervention: randomized, double-blind, placebo-controlled phase 3 trial at 11 centers in Norway, with early-stage Parkinson disease participants randomized to oral nicotinamide riboside 500 mg twice daily or placebo for 52 weeks.
  • Primary efficacy result: nicotinamide riboside did not improve total MDS-UPDRS parts I-III and had a statistically worse adjusted mean change than placebo over 52 weeks.
  • Clinical-importance caveat for the primary endpoint: the adjusted 2.72-point difference was statistically significant but below reported minimal clinically important difference thresholds for improvement or worsening.
  • Key secondary outcomes: five prespecified secondary endpoints included MDS-UPDRS parts I, II, III, DAT SPECT imaging, and NMSS; four showed no significant difference, while NMSS worsened more with nicotinamide riboside.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoDetermine whether 52-week oral nicotinamide riboside improves clinical outcomes in early-stage Parkinson disease compared with placebo.Randomized, double-blind, placebo-controlled phase 3 trialExpand

In plain English

Phase 3 randomized, double-blind, placebo-controlled trial (NOPARK) evaluating oral nicotinamide riboside 500 mg twice daily versus placebo for 52 weeks in patients with early Parkinson disease (diagnosis ≤2 years, Hoehn & Yahr <3, DAT imaging–confirmed). Primary outcome was change from baseline to week 52 in total MDS‑UPDRS (parts I–III) analyzed with a mixed model for repeated measures. In the primary analysis (n = 393), the MDS‑UPDRS total score increased by 2.45 points (95% CI, 0.80–4.10) with nicotinamide riboside and decreased by 0.27 points (95% CI, −1.95 to 1.40) with placebo, yielding an adjusted mean difference of 2.72 points (95% CI, 0.47–4.98) favoring placebo (P = .02). The trial conclusion was that nicotinamide riboside did not improve clinical outcomes and was associated with worse outcomes than placebo over 52 weeks.

Key findings

  • In the primary efficacy analysis, 52 weeks of nicotinamide riboside resulted in a statistically worse change in total MDS‑UPDRS compared with placebo.Adjusted mean difference 2.72 points (95% CI, 0.47–4.98) favoring placebo; P = .02
“Randomized, double-blind, placebo-controlled, phase 3 clinical trial conducted at 11 centers in Norway.”
What this piece can’t prove
  • Study population limited to early-stage, DAT-confirmed Parkinson disease (diagnosis ≤2 years, Hoehn & Yahr <3), which may limit generalizability to later-stage or unconfirmed cases.

2 further details could not be confirmed from the summary.

2human in vivoAssess effects of nicotinamide riboside vs placebo on key secondary outcomes including MDS-UPDRS subparts, dopamine transporter SPECT imaging findings, and nonmotor symptom burden (NMSS).Randomized, double-blind, placebo-controlled phase 3 RCT; 52-week interventionExpand

In plain English

In the randomized, double-blind, placebo-controlled NOPARK phase 3 trial (52 weeks, nicotinamide riboside 500 mg twice daily vs placebo) the five prespecified key secondary outcomes were the individual MDS-UPDRS parts I, II, and III, dopamine transporter (DAT) SPECT imaging findings, and the Non-Motor Symptoms Scale (NMSS). Four of the five secondary outcomes showed no significant between-group differences. Nonmotor symptom burden (NMSS) worsened more with nicotinamide riboside than with placebo (adjusted mean difference 4.22; 95% CI, 1.07–7.37; P = .009).

Key findings

  • Nonmotor symptom burden (NMSS) worsened more with nicotinamide riboside than with placebo over 52 weeks.Adjusted mean difference 4.22 points (95% CI, 1.07–7.37); P = .009
  • No significant between-group differences were observed for MDS-UPDRS part I (individual nonmotor aspects) as a prespecified secondary outcome.
“The 5 key secondary outcomes were the individual parts I, II, and III of the MDS-UPDRS; dopamine transporter single-photon emission computed tomography brain imaging findings; and the Non-Motor Symptoms Scale score (NMSS).”
What this piece can’t prove
  • For four secondary outcomes the abstract does not report effect estimates, confidence intervals, or P values.
  • Abstract does not report whether or how multiple comparisons across the five key secondary endpoints were adjusted.

3 further details could not be confirmed from the summary.

3human in vivoEvaluate safety/tolerability of nicotinamide riboside vs placebo over 52 weeks (serious adverse events and overall safety population).Randomized, double-blind, placebo-controlled phase 3 trial — safety population analysisExpand

In plain English

In the 52-week randomized, double-blind, placebo-controlled NOPARK trial, serious adverse events (SAEs) in the safety population occurred in 17 of 205 (8.3%) participants randomized to nicotinamide riboside and 29 of 205 (14.1%) participants randomized to placebo.

Key findings

  • Serious adverse events occurred in 17 of 205 (8.3%) participants receiving nicotinamide riboside and 29 of 205 (14.1%) receiving placebo in the safety population.17/205 (8.3%) vs 29/205 (14.1%)
“Serious adverse events occurred in 17 (8.3%) of 205 participants receiving nicotinamide riboside and 29 (14.1%) of 205 receiving placebo in the safety population.”
What this piece can’t prove
  • No event-level or system-organ-class breakdown of SAEs is provided.

4 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 15 candidate papers

Candidate

J012 NAD-HD: a randomized clinical trial of nicotinamide riboside in Huntington’s disease

J: Clinical Therapeutics · 2024 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.